Raynauds Disease - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Raynauds Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Raynauds Disease - Pipeline Review, H1 2015’, provides an overview of the Raynauds Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Raynauds Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Raynauds Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Raynauds Disease Overview 7
Therapeutics Development 8
Pipeline Products for Raynauds Disease - Overview 8
Pipeline Products for Raynauds Disease - Comparative Analysis 9
Raynauds Disease - Therapeutics under Development by Companies 10
Raynauds Disease - Therapeutics under Investigation by Universities/Institutes 11
Raynauds Disease - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Raynauds Disease - Products under Development by Companies 15
Raynauds Disease - Products under Investigation by Universities/Institutes 16
Raynauds Disease - Companies Involved in Therapeutics Development 17
Allergan, Inc. 17
Apricus Biosciences, Inc. 18
Azevan Pharmaceuticals, Inc. 19
Bayer AG 20
Human Stem Cells Institute 21
Mezzion Pharma Co. Ltd. 22
Nippon Shinyaku Co., Ltd. 23
Teva Pharmaceutical Industries Limited 24
Raynauds Disease - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
alprostadil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ELS-140 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MDT-012 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
onabotulinumtoxin A - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
riociguat - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
selexipag - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit Alpha 2 Adrenergic Receptor for Raynauds Disease - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SRX-251 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
udenafil - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Raynauds Disease - Recent Pipeline Updates 51
Raynauds Disease - Dormant Projects 66
Raynauds Disease - Discontinued Products 67
Raynauds Disease - Product Development Milestones 68
Featured News & Press Releases 68
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa 68
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon 68
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 69
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 70
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon 70
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon 71
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa 71
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for Raynauds Disease, H1 2015 8
Number of Products under Development for Raynauds Disease - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Raynauds Disease - Pipeline by Allergan, Inc., H1 2015 17
Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H1 2015 18
Raynauds Disease - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 19
Raynauds Disease - Pipeline by Bayer AG, H1 2015 20
Raynauds Disease - Pipeline by Human Stem Cells Institute, H1 2015 21
Raynauds Disease - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 22
Raynauds Disease - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 23
Raynauds Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Raynauds Disease Therapeutics - Recent Pipeline Updates, H1 2015 51
Raynauds Disease - Dormant Projects, H1 2015 66
Raynauds Disease - Discontinued Products, H1 2015 67